Dry eye is a multifactorial disease of the ocular surface characterized by a loss of homeostasis of the tear film, and accompanied by ocular symptoms, in which tear film instability and hyperosmolarity, ocular surface inflammation and damage, and neurosensory abnormalities play etiological roles. (International Dry Eye Workshop, TFOS, 2017)
Breakthrough papers Parra et al . 2010 and Quallo et al. 2015, leaded by the group of Professor Carlos Belmonte at the Alicante Neurosciences Institute, reported the discovery that Ocular surface wetness and eye blinking were regulated by TRPM8-dependent cold thermoreceptors of the cornea, suggesting that the pharmacological modulation of specific neural pathways could open new possibilities for treating Dry Eye Disease and other diseases of the mucosae.
AVX PHARMA is leading this strategy by developing selective TRPM8 agonist AVX-012 Ophthalmic Solution, a novel, ocular neurosensory drug therapy currently in Phase 2 clinical trials for Dry Eye Disease, and at earlier stage of development for Vaginal Dryness.